Literature DB >> 11976227

Lithium in bipolar mood disorder.

Timothy G Dinan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11976227      PMCID： PMC1122989          DOI： 10.1136/bmj.324.7344.989

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Lithium salts in the treatment of psychotic excitement.

Authors:  J F J CADE
Journal:  Med J Aust       Date:  1949-09-03       Impact factor: 7.738

Review 2.  Lithium: balancing risks and benefits.

Authors:  J Cookson
Journal:  Br J Psychiatry       Date:  1997-08       Impact factor: 9.319

3.  A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.

Authors:  C L Bowden; J R Calabrese; S L McElroy; L Gyulai; A Wassef; F Petty; H G Pope; J C Chou; P E Keck; L J Rhodes; A C Swann; R M Hirschfeld; P J Wozniak
Journal:  Arch Gen Psychiatry       Date:  2000-05

Review 4.  Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Authors:  K A Macritchie; J R Geddes; J Scott; D R Haslam; G M Goodwin
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 5.  The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.

Authors:  G S Sachs; D J Printz; D A Kahn; D Carpenter; J P Docherty
Journal:  Postgrad Med       Date:  2000-04       Impact factor: 3.840
  5 in total
  9 in total

1.  New trial should clarify lithium use in bipolar disorder.

Authors:  John Geddes; Guy Goodwin; Jennifer Rendell; Jane Hainsworth; Emma Van der Gucht; Heather Young
Journal:  BMJ       Date:  2002-08-24

2.  Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence.

Authors:  Kenneth I Shulman; Paula Rochon; Kathy Sykora; Geoffrey Anderson; Muhammad Mamdani; Susan Bronskill; Chau T T Tran
Journal:  BMJ       Date:  2003-05-03

3.  Nationwide reconnaissance of contaminants of emerging concern in source and treated drinking waters of the United States: Pharmaceuticals.

Authors:  Edward T Furlong; Angela L Batt; Susan T Glassmeyer; Mary C Noriega; Dana W Kolpin; Heath Mash; Kathleen M Schenck
Journal:  Sci Total Environ       Date:  2017-02-01       Impact factor: 7.963

4.  Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD.

Authors:  Robert C Young; Herbert C Schulberg; Ariel G Gildengers; Martha Sajatovic; Benoit H Mulsant; Laszlo Gyulai; John Beyer; Lauren Marangell; Mark Kunik; Thomas Ten Have; Martha L Bruce; Ruben Gur; Patricia Marino; Jovier D Evans; Charles F Reynolds; George S Alexopoulos
Journal:  Bipolar Disord       Date:  2010-02       Impact factor: 6.744

Review 5.  Use of lithium in the treatment of bipolar disorder in late-life.

Authors:  Ramsey D'Souza; Tarek K Rajji; Benoit H Mulsant; Bruce G Pollock
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

6.  Role of extended release quetiapine in the management of bipolar disorders.

Authors:  Rayan K Al Jurdi; Lena A Dixit; Martha Sajatovic
Journal:  Neuropsychiatr Dis Treat       Date:  2010-03-24       Impact factor: 2.570

7.  Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review.

Authors:  Rachael L Fleurence; Mary Lou Chatterton; Julia M Dixon; Kitty Rajagopalan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 8.  The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders.

Authors:  Kaizad R Munshi; Tanya Oken; Danielle J Guild; Harsh K Trivedi; Betty C Wang; Peter Ducharme; Joseph Gonzalez-Heydrich
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-10

9.  Lithium Stabilizes the Mood of Bipolar Patients by Depolarizing the Neuronal Membrane Via Quantum Tunneling through the Sodium Channels.

Authors:  Abdallah Barjas Qaswal
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.